Advances in Targeted Therapy for Neurofibromatosis Type 2 (NF2)-Associated Vestibular Schwannomas

被引：0
|
作者：
Evan C. Cumpston
Steven D. Rhodes
Charles W. Yates
机构：
[1] Indiana University School of Medicine,Department of Otolaryngology
[2] Indiana University School of Medicine,Head & Neck Surgery
[3] Indiana University School of Medicine,Department of Pediatrics
来源：
Current Oncology Reports | 2023年 / 25卷
关键词：
Vestibular schwannoma; Neurofibromatosis type 2; Molecular targeted drug therapy; Medical therapy; Selective therapeutics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：531 / 537
页数：6
相关论文
共 50 条
  • [1] Advances in Targeted Therapy for Neurofibromatosis Type 2 (NF2)-Associated Vestibular Schwannomas
    Cumpston, Evan C.
    Rhodes, Steven D.
    Yates, Charles W.
    [J]. CURRENT ONCOLOGY REPORTS, 2023, 25 (05) : 531 - 537
  • [2] Identification of three neurofibromatosis type 2 (NF2) gene mutations in vestibular schwannomas
    Sainz, J
    Figueroa, K
    Baser, ME
    Pulst, SM
    [J]. HUMAN GENETICS, 1996, 97 (01) : 121 - 123
  • [3] Differential diagnosis of type 2 neurofibromatosis: molecular discrimination of NF2 and sporadic vestibular schwannomas
    Wu, CL
    Thakker, N
    Neary, W
    Black, G
    Lye, R
    Ramsden, RT
    Read, AP
    Evans, DGR
    [J]. JOURNAL OF MEDICAL GENETICS, 1998, 35 (12) : 973 - 977
  • [4] CpG island hypermethylation of the neurofibromatosis type 2 (NF2) gene is rare in sporadic vestibular schwannomas
    Kullar, P. J.
    Pearson, D. M.
    Malley, D. S.
    Collins, V. P.
    Ichimura, K.
    [J]. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2010, 36 (06) : 505 - 514
  • [5] Evaluation of neurofibromatosis 2 (NF2) clinical diagnostic criteria in NF2 patients without bilateral vestibular schwannomas.
    Baser, ME
    Friedman, JM
    Wallace, A
    Ramsden, RT
    Evans, DGR
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2000, 67 (04) : 56 - 56
  • [6] Management of Neurofibromatosis Type 2 Associated Vestibular Schwannomas
    Jia, Huan
    Lahlou, Ghizlene
    Wu, Hao
    Sterkers, Olivier
    Kalamarides, Michel
    [J]. CURRENT OTORHINOLARYNGOLOGY REPORTS, 2021, 9 (02) : 170 - 176
  • [7] Management of Neurofibromatosis Type 2 Associated Vestibular Schwannomas
    Huan Jia
    Ghizlene Lahlou
    Hao Wu
    Olivier Sterkers
    Michel Kalamarides
    [J]. Current Otorhinolaryngology Reports, 2021, 9 : 170 - 176
  • [8] Bevacizumab in Neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation
    Morris, Katrina A.
    Golding, John F.
    Axon, Patrick R.
    Afridi, Shazia
    Blesing, Claire
    Ferner, Rosalie E.
    Halliday, Dorothy
    Jena, Raj
    Pretorius, Pieter M.
    Evans, D. Gareth
    McCabe, Martin G.
    Parry, Allyson
    [J]. NEURO-ONCOLOGY PRACTICE, 2016, 3 (04) : 281 - 289
  • [9] Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis
    Bachir, Suha
    Shah, Sanjit
    Shapiro, Scott
    Koehler, Abigail
    Mahammedi, Abdelkader
    Samy, Ravi N.
    Zuccarello, Mario
    Schorry, Elizabeth
    Sengupta, Soma
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (02) : 1 - 12
  • [10] Results of Bevacizumab Therapy on Hearing Loss Associated with Vestibular Schwannomas in NF2: Three Patients
    Termsarasab, Pichet
    Rogers, Lisa
    Megerian, Cliff
    Bambakidis, Nicholas
    [J]. NEUROLOGY, 2012, 78
12345